人工智能在生命科学商业化中的应用白皮书：来自2025年商业领袖调查的战略洞察与实践建议

White Paper AI in Life SciencesCommercialization Strategic insights and practical recommendationsfrom 2025 survey of Commercial Leaders SHRAVAN KOTAKONDA, VP, Commercial Solutions, Strategic Operations, IQVIADR. PRAVINDRA AWASTHI, Principal, Market & Competitive Intelligence, IQVIA Table of contents Executive summary1Survey methodology2State of AI adoption3AI investment, maturity, and organizational readiness to scale AI3AI impact by commercial function5Barriers to scale6Vendor strategy and partnership models7Outlook8Conclusion: From ambition to advantage9Playbook for scaling AI10Acknowledgements11About the authors12 Executive summary Artificial Intelligence (AI) has become an indispensable component of life sciencescommercialization, reshaping how companies allocate resources, engagecustomers, and drive growth. To understand this transformation, IQVIA surveyed107 senior commercial leaders across five critical areas: adoption and maturity,investment and ROI, impact by function, barriers to scale, and partnershipstrategy. Our goal was to capture the full journey from AI ambition to real-worldexecution to help leaders benchmark their progress, understand how peersare adapting their strategies, and make informed decisions about where tofocusnext. Survey findings show that AI is moving rapidly fromexperimentation to execution. Over 80% of organizationshave advanced beyond pilots, and more than a thirdnow describe themselves as “AI Advanced.” AI Advancedorganizations are defined as those that have widelyadopted AI technologies, with a clear strategy andongoing optimization. organizations still face data readiness gaps, partnershipsare helping accelerate progress. 89% of those surveyedare already co-developing or actively considering co-development of AI solutions with external vendors, withselection driven by criteria such as domain expertise,data security, and proven innovation. All of these insights begin to tell the story of what lifesciences organizations need to successfully adopt, andutilize, AI moving forward. The survey results revealthat successful organizations demonstrate the ability toembed AI into cross-functional workflows, move frompilots to broad adoption, and build resilient, data-drivencommercial models. Their experience shows that thenext wave of value will come from disciplined execution,strong governance, and the right partnerships — notjust technology. Investment in AI is rising, and the returns are real.Nearly half of the surveyed companies dedicate morethan 20% of their commercial budgets to AI, withanother quarter investing between 11% and 20%.This level of commitment reflects AI’s growing role incommercial strategy with proven results. The returns arecompelling: 58% of leaders report achieving 2X ROI fromtheir AI initiatives within a single year, with 7% seeing3Xor more. However, scaling AI — and realizing its full value —remains challenging. Data privacy, legacy systems, andtalent shortages are the most common barriers. Notably,36% of organizations say their data is either “mostlyinsufficient” or only “moderately sufficient” to supportAI, highlighting a persistent gap in data readiness. Justover half (52%) rate their data as “mostly sufficient,”and only 11% say it is “fully sufficient.” Because many For leaders looking to translate these insights intoaction, the “Playbook for scaling AI” section outlinessix practical moves to scale AI with impact. All data and insights are from a May 2025 IQVIA Survey onAI in Life Sciences Commercialization. Survey methodology To understand how AI is transforming life sciencescommercialization, in May 2025, IQVIA conducted asurvey of senior commercial leaders across the industry.The goal was to gain a comprehensive view of howorganizations are investing in, deploying, and scalingAI — and what barriers and enablers are shapingthatjourney. The survey included 107 respondents, representinga diverse mix of geographies, company sizes, andcommercial functions. Participants held senior rolesacross Sales, Marketing, Market Access, Compliance, andData Operations, ensuring a well-rounded perspectiveon both strategic priorities and operational realities. In addition to multiple-choice and scaled-response questions, the survey included free-text questions to captureemerging use cases, data challenges, and vendor experiences in respondents’ own words. These qualitative insightswere analyzed alongside quantitative data to surface patterns, priorities, and points of divergence across the industry. State of AI adoption AI investment, maturity, and organizational readiness to scale AI For life sciences companies today, investment in AI has become a defining feature of commercial strategy. Accordingto the IQVIA survey, nearly half of organizations (44%) now dedicate more than 20% of their commercial budget toAI initiatives. Only 5% — allocate less than 5% of their commercial budget to AI, underscoring how rare it is for AI toremain a marginal spend